iShares MSCI United Kingdom (FTSE) vs Vaxcyte Inc. Common Stock — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.91 (market cap $3.69B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.8× iShares MSCI United Kingdom (FTSE)'s market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, iShares MSCI United Kingdom (FTSE) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 48 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| EWU | PCVX | |
|---|---|---|
Market Cap | $3.69B | $10.51B |
Volume | 701,016 | 2,644,694 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $73.82 |
52-Week Low | $41.34 | $40.32 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.82 with a modest 0.26% daily gain, though technical indicators signal a bearish trend with moving averages and overall momentum pointing downward. The stock faces headwinds from UK economic concerns including rising gilt yields and inflation pressures. Recent news highlights sector-specific volatility in UK banking and housing markets, creating a challenging environment for this UK-focused ETF.
The outlook remains cautious given macroeconomic pressures on UK assets. Investment opportunity exists for contrarian investors betting on UK recovery, but risks include persistent inflation, rising interest rates, and political uncertainty around upcoming budget decisions that could impact financial and housing sectors significantly.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →